{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034153","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.059934+00:00","generated_at":"2026-06-04T12:07:04.833408+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rani Therapeutics FY2023 net loss $67.9M; cash $48.5M; positive Phase 1 for RT-111 oral antibody","bullets":["Net loss for FY2023 was $67.9M ($63.3M in 2022); cash and equivalents $48.5M (down from $98.5M at year-end 2022).","Positive topline Phase 1 data for RT-111 (oral anti-IL12/23 antibody): high bioavailability, well-tolerated, no serious adverse events.","Strategic restructuring: discontinued RT-101, paused RT-105/110, reduced workforce, cost savings extend cash runway into 2025.","Phase 2 trial of RT-102 (teriparatide for osteoporosis) to start in 2024; RaniPill HC ready for Phase 1 in H2 2024.","Preclinical data showed transenteric delivery of GLP-1 triagonist elicits rapid weight loss; successful oral delivery of Humira via RaniPill HC."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034153","json":"https://secwatch.observer/filing/0000950170-24-034153.json","markdown":"https://secwatch.observer/filing/0000950170-24-034153.md","text":"https://secwatch.observer/filing/0000950170-24-034153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024034153/0000950170-24-034153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024034153/rani-20240320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T12:07:04.833408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52df98547a59bcb1e826966cb8474019474b3902","claim":"Rani Therapeutics Holdings, Inc. reported financial results for fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 20, 2024, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024034153/0000950170-24-034153-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}